K
Klaus Romero
Researcher at Critical Path Institute
Publications - 94
Citations - 2341
Klaus Romero is an academic researcher from Critical Path Institute. The author has contributed to research in topics: Drug development & Clinical trial. The author has an hindex of 24, co-authored 79 publications receiving 1681 citations.
Papers
More filters
Journal ArticleDOI
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Scott C. Neu,Judy Pa,Walter A. Kukull,Duane Beekly,Amanda B. Kuzma,Prabhakaran Gangadharan,Li-San Wang,Klaus Romero,Stephen P. Arneric,Alberto Redolfi,Daniele Orlandi,Giovanni B. Frisoni,Rhoda Au,Sherral Devine,Sanford Auerbach,Ana Espinosa,Mercè Boada,Agustín Ruiz,Sterling C. Johnson,Rebecca L. Koscik,Jiun-Jie Wang,Jiun-Jie Wang,Wen Chuin Hsu,Yao Liang Chen,Arthur W. Toga +24 more
TL;DR: Contrary to long-standing views, men and women with the APOE &egr;3/&egR;4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Journal ArticleDOI
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.
Ronald D. Perrone,Mohamad Samer Mouksassi,Klaus Romero,Frank S. Czerwiec,Arlene B. Chapman,Berenice Gitomer,Vicente E. Torres,Dana C. Miskulin,Steve Broadbent,Jean F. Marier +9 more
TL;DR: TKV was the most important prognostic term for 30% decline in eG FR in autosomal dominant polycystic kidney disease patients with and without preserved baseline eGFR and was formally qualified as a prognostic enrichment biomarker for selecting patients at high risk for a progressive decline in renal function for inclusion in interventional clinical trials.
Journal ArticleDOI
Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis
James A. Rogers,Daniel Polhamus,William R. Gillespie,Kaori Ito,Klaus Romero,Ruolun Qiu,Diane Stephenson,Marc R. Gastonguay,Brian Corrigan +8 more
TL;DR: An adequate BR meta-analysis model for ADAS-cog using both summary-level and patient-level data was developed, allowing for simultaneous fitting of summary and patient level data, and constrains values to the range of the original instrument for simulation purposes.
Journal ArticleDOI
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
TL;DR: The HFS-TB model is highly accurate at forecasting optimal drug exposures, doses, and dosing schedules for use in the clinic, and the forecasting accuracy of a completely unreliable tool was also calculated.
Journal ArticleDOI
Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis
TL;DR: There is a need for formal quantitative analyses of how well DDTs forecast clinical outcomes, and no single nonclinical in vitro or animal model recapitulates all aspects of human tuberculosis.